In the 90s, scientists discovered the Human Endocannabinoid System, a physiological system made of chemical compounds and Cannabinoid receptors known to regulate the body and keep us balanced. It was discovered that human bodies produce their own natural cannabinoids (“endo” = “made in the body”).
In an interview with Dr. Ethan Russo, a board-certified Neurologist and former Chairman of the International Association for Cannabinoid Medicines, he says “Cannabidiol is an endocannabinoid modulator. In other words, when given chronically, it actually increases the gain of system, which is, at its core, a homeostatic regulator. To explain that: homeostasis is a state of balance. Many diseases interfere with a balance in a given system and if we can bring that balance back to where it should be, there’ll be improvement in the overall condition. This is one reason that cannabidiol is such a versatile medicine because so many disorders operate on that kind of level. So, if there’s too much activity in a system, homeostasis requires that it be brought back down. If there’s too little, it’s got to come up.”
What is Clinical Endocannabinoid Deficiency (CECD)?
According to Dr. Russo, “If you don’t have enough endocannabinoids, you have pain where there shouldn’t be pain. You would be sick, meaning nauseated. You would have a lowered seizure threshold. And just a whole litany of other problems.” In his publication “Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes” it is stated that “If endocannabinoid function were decreased, it follows that a lowered pain threshold would be operative, along with derangements of digestion, mood, and sleep among the almost universal physiological systems subserved by the endocannabinoid system.”
In his research, it occurred to Dr. Russo that several common ailments seem to have similar patterns consistent with CECD, especially migraine, irritable bowel syndrome, and fibromyalgia.
In a study examining CECD, “Cannabinoids have similarly demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms that promote pain in headache, fibromyalgia, IBS and related disorders” concluding that these disorders and other related conditions “display common clinical, biochemical and pathophysiological patterns that suggest an underlying CECD that may be suitably treated with cannabinoid medicines.”
In another study involving 28 patients with Fibromyalgia, “After 2 hours of cannabis use, VAS (visual analogue scales) scores showed a statistically significant reduction of pain and stiffness, enhancement of relaxation, and an increase in somnolence and feeling of well being. The mental health component summary score was significantly higher in cannabis users than in non-users. ”
In this day and age, there are so many medical studies indicating that Cannabidiol may be the answer to many conditions. Dr. Russo believes that CECD could be the root not just for migraines, fibromylagia, and IBS, but also MS, Parkinson’s, Huntington’s disease, depression, cystic ﬁbrosis, glaucoma, post-traumatic stress disorder (PTSD) and bipolar disease, and many more diseases.
At Procana, we constantly receive feedback from consumers and practitioners about how our products are helping them find relief where other treatments have not been effective.
Disclaimer: Procana makes no claims to diagnose, treat or cure the above conditions. Clinical research, case studies and articles regarding cannabinoids are for informational purposes only. The above statements have not been approved by the FDA. Please consult your physician to see if Procana is right for you.